A novel melittin-MhIL-2 fusion protein inhibits the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth |
| |
Authors: | Mingjun Liu Jinbao Zong Zimin Liu Ling Li Xu Zheng Bin Wang Guirong Sun |
| |
Affiliation: | 1. Department of Clinical Laboratory, The Affiliated Hospital of Medical College, Qingdao University, No.16 Jiangsu Road, Qingdao, 266003, China 2. Department of Oncology, The Affiliated Hospital of Medical College, Qingdao University, No.16 Jiangsu Road, Qingdao, 266003, China 3. Key Laboratory of Medicine and Biotechnology, Qingdao University Medical College, No.308 Ningxia Road, Qingdao, 266071, China
|
| |
Abstract: | In the current study, we produced a novel fusion protein (melittin-mutant human interleukin 2, melittin-MhIL-2) comprising a mutant human interleukin 2 (Arg88/Ala125) genetically linked to melittin. The plasmid pET15b-melittin-MhIL-2 (Arg88/Ala125) was transformed into E. coli for protein expression. The expressed melittin-MhIL-2 protein was purified using a series of purification steps. The interleukin 2 (IL-2) activity of melittin-MhIL-2 fusion protein was compared with recombinant human interleukin 2 (rhIL-2) for its ability to induce CTLL-2 proliferation. Moreover, the fusion protein directly inhibits the growth of human ovarian cancer SKOV3 cells in vitro. In an in vivo initial experiment, the fusion protein inhibited tumor growth in ovarian cancer mice. In conclusion, we generated a novel melittin-MhIL-2 fusion protein that retained functional activity of IL-2 and melittin and inhibited tumor growth in vivo. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|